Free Access
Editorial
| Issue |
Med Sci (Paris)
Volume 40, Number 2, Février 2024
|
|
|---|---|---|
| Page(s) | 119 - 120 | |
| Section | Editorial | |
| DOI | https://doi.org/10.1051/medsci/2023222 | |
| Published online | 27 February 2024 | |
- Keeler CE. Gene Therapy. J Hered 1947 ; 38 : 294–8. [Google Scholar]
- Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002 ; 76 : 295–8. [CrossRef] [PubMed] [Google Scholar]
- Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009 ; 96 : 151–7. [CrossRef] [PubMed] [Google Scholar]
- Chneiweiss H. 2023 : premiers succès et nouveaux enjeux de l’édition du génome en thérapeutique humaine. Med Sci (Paris) 2023 ; 39 : 589–90. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Shieh PB, Kuntz NL, Dowling JJ. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO) : a multinational, open-label, dose-escalation trial. Lancet Neurol 2023 ; 22 : 1125–39. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.